Cybin (CYBN) Stock Rises Following Positive Trial Results
After Cybin Inc. (NYSE: CYBN) released encouraging results from its Phase 2 study of CYB003, the company’s shares jumped 11.90% in early trading to $12.98.
After Cybin Inc. (NYSE: CYBN) released encouraging results from its Phase 2 study of CYB003, the company’s shares jumped 11.90% in early trading to $12.98.
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.